Company intelligence / Profile preview

Knight

Montreal, Quebec, Canada

Ownership: Private
Employees: ~700
Development stage: Other

Overview

Knight Therapeutics commercializes dozens of specialty pharmaceutical and branded generic products in Canada and ten Latin American countries, with most products focused on commercial and late-stage launches[1][2][4]. The company is not engaged in novel drug discovery, but specializes in in-licensing and commercialization of innovative and specialty medicines. Recent launches and approvals include Minjuvi (tafasitamab) for lymphoma, Imvexxy (estradiol), Bijuva (estradiol and progesterone), and others in both North and South America[1].

Therapeutic areas: Women's HealthInfectious DiseasesNeurologyGastroenterologyHematologyOncology
Modalities: Small moleculeBiologicMonoclonal antibodyImplantCombination product
Industry: Biotech

Partnerships

Rigel PharmaceuticalsHelsinnNovartisEndo Operations LimitedPaladin Pharma

Beyond the preview

Go deeper on Knight.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Knight.

Explore the full profile